Renaissance Technologies LLC Sells 224,390 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX)

Renaissance Technologies LLC cut its holdings in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) by 30.8% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 503,300 shares of the biotechnology company’s stock after selling 224,390 shares during the quarter. Renaissance Technologies LLC’s holdings in Aldeyra Therapeutics were worth $1,666,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of ALDX. Price T Rowe Associates Inc. MD increased its holdings in shares of Aldeyra Therapeutics by 7.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 48,273 shares of the biotechnology company’s stock valued at $158,000 after acquiring an additional 3,446 shares in the last quarter. Providence Wealth Advisors LLC increased its position in Aldeyra Therapeutics by 16.3% during the second quarter. Providence Wealth Advisors LLC now owns 25,000 shares of the biotechnology company’s stock valued at $84,000 after acquiring an additional 3,500 shares during the last quarter. Laidlaw Wealth Management LLC lifted its stake in shares of Aldeyra Therapeutics by 32.6% in the 2nd quarter. Laidlaw Wealth Management LLC now owns 16,875 shares of the biotechnology company’s stock worth $56,000 after purchasing an additional 4,150 shares during the period. BNP Paribas Financial Markets raised its position in Aldeyra Therapeutics by 23.4% in the first quarter. BNP Paribas Financial Markets now owns 25,278 shares of the biotechnology company’s stock worth $83,000 after acquiring an additional 4,797 shares during the period. Finally, Hennion & Walsh Asset Management Inc. grew its position in shares of Aldeyra Therapeutics by 8.6% during the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 88,122 shares of the biotechnology company’s stock valued at $292,000 after acquiring an additional 6,944 shares during the period. 59.71% of the stock is currently owned by institutional investors.

Aldeyra Therapeutics Trading Down 1.3 %

Shares of ALDX opened at $5.23 on Friday. The company has a market capitalization of $310.74 million, a PE ratio of -10.25 and a beta of 1.45. Aldeyra Therapeutics, Inc has a 12-month low of $1.42 and a 12-month high of $6.55. The business’s 50 day moving average is $5.17 and its 200 day moving average is $4.25.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Aldeyra Therapeutics in a research report on Friday, August 9th.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.